An Open-label Trial With TMC278 25 mg q.d. in Combination With a Background Regimen Containing 2 N(t)RTI's in HIV-1 Infected Subjects Who Participated in TMC278 Clinical Trials and Were Still Benefitting From Treatment With TMC278
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Rilpivirine (Primary) ; Nucleotide reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Adverse reactions; Registrational
- Sponsors Janssen R&D Ireland
- 19 Jan 2018 Planned primary completion date changed from 29 Dec 2017 to 31 Dec 2018.
- 10 Jun 2017 Biomarkers information updated
- 14 Mar 2017 Planned End Date changed from 1 Dec 2019 to 31 Dec 2018.